At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 33 enrolled
Drug / intervention
Ranolazine +1 moredrug
Likely dose
Ranolazine 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic Syndrome.
In Brief
A Phase 4 clinical trial evaluating Ranolazine and Placebo for Stable Angina and Metabolic Syndrome. Completed, enrolled 33 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effects of ranolazine on different markers of cardiometabolic disease in women with stable angina.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStable Angina, Metabolic Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartSep 2015
Primary CompletionDec 2018
Study CompletionMay 2019
TodayJul 2026
First PostedSep 30, 2014
Enrollment StartSep 1, 2015
Primary CompletionDec 17, 2018
Study CompletionMay 17, 2019
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.8 years ago
Interventions
Ranolazinedrug
Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24
Placeboother
Matching placebo tablets daily for 24 weeks.